Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kura Oncology

Kura Oncology
2014 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
KURA STOCK SYMBOL
1 INVESTMENTS
$20.32 SHARE PRICE (As of Tuesday Closing)
Description

Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through United States.

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 11119 North Torrey Pines Road
  • Suite 125, La Jolla
  • San Diego, CA 92037
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kura Oncology’s full profile, request a free trial.

Kura Oncology Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$10.20 - $22.00 $776M $20.33 -$1.64 334K 38.2M

Kura Oncology Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 461,739 352,882 368,535 58,810
Revenue 0 0 0 0
EBITDA (62,670) (62,636) (35,267) (27,451)
Net Income (59,783) (60,447) (35,434) (27,560)
Total Assets 169,617 182,379 95,851 69,821
Total Debt 7,500 7,500 7,098 7,324
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kura Oncology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Kura Oncology‘s full profile, request access.

Request full access to PitchBook

Kura Oncology Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000000 06-Mar-2015 000000000000000000 Holding Companies
To view this company’s complete investment and acquisition history, request access »

Kura Oncology Executive Team (8)

Name Title Board
Seat
Contact
Info
Marc Grasso MD Chief Financial Officer & Chief Business Officer
Yi Liu Ph.D Co-Founder & Chief Scientific Officer
Pingda Ren Ph.D Co-Founder & Senior Vice President, Chemistry and Pharmaceutical Sciences
Antonio Gualberto Ph.D Co-Founder & Chief Medical Officer
Annette North Senior Vice President & General Counsel

1 Former Executive

You’re viewing 5 of 8 executives. Get the full list »

Kura Oncology Board Members (3)

Name Representing Role Since Contact
Info
000000 0000000 Self Board Member 000 0000
000000 0000000 Self Board Member 000 0000
0000 000000 00.0 Self Co-Founder, Chairman, President & Chief Executive Officer 000 0000